425 related articles for article (PubMed ID: 8351515)
21. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
[TBL] [Abstract][Full Text] [Related]
22. Specific inhibition of interleukin-10 production in murine macrophage-like cells by phosphorothioate antisense oligonucleotides.
Arima H; Takahashi M; Aramaki Y; Sakamoto T; Tsuchiya S
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):319-27. PubMed ID: 9743469
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.
Lisziewicz J; Sun D; Metelev V; Zamecnik P; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1993 May; 90(9):3860-4. PubMed ID: 8483903
[TBL] [Abstract][Full Text] [Related]
24. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao WY; Han FS; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
[TBL] [Abstract][Full Text] [Related]
25. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
26. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation.
Alt M; Renz R; Hofschneider PH; Caselmann WH
Arch Virol; 1997; 142(3):589-99. PubMed ID: 9349305
[TBL] [Abstract][Full Text] [Related]
27. Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study.
Tonkinson JL; Guvakova M; Khaled Z; Lee J; Yakubov L; Marshall WS; Caruthers MH; Stein CA
Antisense Res Dev; 1994; 4(4):269-78. PubMed ID: 7537561
[TBL] [Abstract][Full Text] [Related]
28. Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses.
Archambault D; Stein CA; Cohen JS
Arch Virol; 1994; 139(1-2):97-109. PubMed ID: 7826217
[TBL] [Abstract][Full Text] [Related]
29. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.
Agrawal S; Jiang Z; Zhao Q; Shaw D; Cai Q; Roskey A; Channavajjala L; Saxinger C; Zhang R
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2620-5. PubMed ID: 9122245
[TBL] [Abstract][Full Text] [Related]
30. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
31. Antisense knockdown of PKC-alpha using LNA-oligos.
Hansen JB; Westergaard M; Thrue CA; Giwercman B; Oerum H
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1607-9. PubMed ID: 14565477
[TBL] [Abstract][Full Text] [Related]
32. Use of partially phosphorothioated "antisense" oligodeoxynucleotides for sequence-dependent modulation of hematopoiesis in culture.
Ehrlich G; Patinkin D; Ginzberg D; Zakut H; Eckstein F; Soreq H
Antisense Res Dev; 1994; 4(3):173-83. PubMed ID: 7849488
[TBL] [Abstract][Full Text] [Related]
33. Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus.
Shoji Y; Shimada J; Mizushima Y; Iwasawa A; Nakamura Y; Inouye K; Azuma T; Sakurai M; Nishimura T
Antimicrob Agents Chemother; 1996 Jul; 40(7):1670-5. PubMed ID: 8807060
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.
Morishita R; Gibbons GH; Kaneda Y; Ogihara T; Dzau VJ
Gene; 1994 Nov; 149(1):13-9. PubMed ID: 7958977
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides.
Yao ZQ; Zhou YX; Wang AL; Bai XF; Yang WS
J Viral Hepat; 1995; 2(2):85-9. PubMed ID: 7493302
[TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
37. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
38. Suppression of influenza virus biopolymers functions and reproduction of the virus by oligodeoxynucleotide derivatives.
Yurchenko LV; Abramova TV; Ivanova EM; Nevinsky GA; Nomokonova NY; Fokina TN; Vlassov VV
Nucleic Acids Symp Ser; 1991; (24):301. PubMed ID: 1841358
[No Abstract] [Full Text] [Related]
39. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
40. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
